- Home
- FRPT vs GLPG Comparison
FRPT vs GLPG Comparison
Compare FRPT & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRPT
- GLPG
- Stock Information
- Founded
- FRPT 2004
- GLPG 1999
- Country
- FRPT United States
- GLPG Belgium
- Employees
- FRPT N/A
- GLPG N/A
- Industry
- FRPT Packaged Foods
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- FRPT Consumer Staples
- GLPG Health Care
- Exchange
- FRPT Nasdaq
- GLPG Nasdaq
- Market Cap
- FRPT 2.4B
- GLPG 2.1B
- IPO Year
- FRPT 2014
- GLPG 2005
- Fundamental
- Price
- FRPT $57.08
- GLPG $30.03
- Analyst Decision
- FRPT Buy
- GLPG Hold
- Analyst Count
- FRPT 17
- GLPG 4
- Target Price
- FRPT $95.19
- GLPG $30.00
- AVG Volume (30 Days)
- FRPT 1.7M
- GLPG 212.4K
- Earning Date
- FRPT 11-03-2025
- GLPG 11-05-2025
- Dividend Yield
- FRPT N/A
- GLPG N/A
- EPS Growth
- FRPT 169.38
- GLPG N/A
- EPS
- FRPT 2.38
- GLPG N/A
- Revenue
- FRPT $1,079,494,000.00
- GLPG $323,674,692.00
- Revenue This Year
- FRPT $15.88
- GLPG $1.77
- Revenue Next Year
- FRPT $11.59
- GLPG $0.44
- P/E Ratio
- FRPT $23.51
- GLPG N/A
- Revenue Growth
- FRPT 16.34
- GLPG 5.43
- 52 Week Low
- FRPT $46.76
- GLPG $22.36
- 52 Week High
- FRPT $164.07
- GLPG $37.78
- Technical
- Relative Strength Index (RSI)
- FRPT 57.45
- GLPG 35.05
- Support Level
- FRPT $48.76
- GLPG $30.92
- Resistance Level
- FRPT $57.35
- GLPG $31.85
- Average True Range (ATR)
- FRPT 2.46
- GLPG 0.81
- MACD
- FRPT 0.50
- GLPG -0.26
- Stochastic Oscillator
- FRPT 96.74
- GLPG 2.96
About FRPT Freshpet Inc.
Freshpet produces and sells premium fresh pet food through its company-owned refrigerators placed in grocery, mass and club, pet specialty, and natural stores. Freshpet primarily targets dogs (96% of 2024 sales), with cats and treats comprising the rest of its sales. Geographically, the company's home US market, where all its food is produced, accounts for about 98% of sales, with exports to Canada, the United Kingdom, and other European countries accounting for the remaining balance.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.